CN111297885A - Application of geranium polysaccharide in preparing liver-protecting medicine - Google Patents
Application of geranium polysaccharide in preparing liver-protecting medicine Download PDFInfo
- Publication number
- CN111297885A CN111297885A CN202010078011.7A CN202010078011A CN111297885A CN 111297885 A CN111297885 A CN 111297885A CN 202010078011 A CN202010078011 A CN 202010078011A CN 111297885 A CN111297885 A CN 111297885A
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- geranium
- liver
- application
- protecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of biotechnology, and particularly relates to preparation of Geranium wilfordii (Geranium wilfordii Maxim.) polysaccharide and application of Geranium wilfordii polysaccharide in development of liver-protecting medicines. The invention adopts an immune liver injury model induced by concanavalin A and investigates the liver protection activity of the immune liver injury model. The experimental result shows that the geranium polysaccharide can obviously reduce the liver function index of mice with liver injury, and can be used for researching and developing liver-protecting medicaments, in particular medicaments for treating immunological liver injury. The invention has important significance for further development and utilization of the geranium wilfordii.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to a preparation method of geranium polysaccharide and application of the geranium polysaccharide in developing a liver-protecting medicine.
Background
Autoimmune hepatitis is chronic hepatitis mediated by autoimmune reaction, and is clinically characterized by serum transaminase AST and ALT elevation, hypergammaglobulinemia and autoantibody positivity, and is interfacial hepatitis mainly characterized by lymphocyte and plasma cell infiltration in histology, and severe hepatitis can develop into liver cirrhosis. At present, the drugs for treating autoimmune hepatitis are some immunosuppressants such as glucocorticoid, and the side effect thereof is obvious and is one of the troubles of clinical treatment. In combination with the practical clinical problems, the search for liver-protecting drugs with low toxicity and remarkable effects is urgent.
Polysaccharides are widely found in plants, algae, fungi and animals, and are one of the most abundant biomacromolecules in nature. Research shows that the polysaccharide component has various pharmacological activities, such as immunity regulation, anti-inflammation, antioxidation, antitumor and the like, and has a plurality of researches and applications in the fields of medicines and health-care foods.
Geranium wilfordii (Geranium wilfordii Maxim.) is a plant of Geranium of Geraniaceae, is one of the common Chinese medicines, and has the effects of dispelling wind-damp, dredging channels and collaterals, and the like. In order to better develop and utilize the effective components of the geranium wilfordii, people aim at the polysaccharide components which are not reported temporarily, and find that the polysaccharide components indeed have remarkable hepatoprotective activity, thus having important significance for further development and utilization of the geranium wilfordii.
Disclosure of Invention
One of the purposes of the invention is to provide a preparation method of geranium polysaccharide; the second purpose is to provide the application of the geranium polysaccharide in preparing the low-toxicity and high-efficiency liver protection medicine; the third purpose is to further develop and utilize the geranium.
In order to achieve the above purpose, the invention provides the following technical scheme:
application of geranium polysaccharide in preparing liver-protecting medicine
The preparation method of the geranium polysaccharide comprises the following steps: pulverizing herba Erodii seu Geranii, defatting with methanol under reflux, extracting with water at 80 deg.C, precipitating with 80% ethanol, deproteinizing the crude polysaccharide obtained by precipitating with ethanol by sevege method, centrifuging, and discarding the precipitate to obtain refined herba Erodii seu Geranii polysaccharide.
The Geranium sibiricum polysaccharide has effect in protecting liver by reducing alanine Aminotransferase (ALT) value and aspartate Aminotransferase (AST) value in blood serum
The dose of Geranium sibiricum polysaccharide is 2-3 times per day, and 0.4-1.8g each time.
The dosage of Geranium polysaccharide is 1g for 3 times per day.
Adding pharmaceutically acceptable adjuvants into the Geranium polysaccharide, and making into tablet, hard capsule, soft capsule, powder, pill, and granule.
Geranium polysaccharide is used as active ingredient or medicinal carrier.
In order to confirm the liver protection activity of the geranium polysaccharide, the invention adopts a ConA induced mouse acute immune liver injury model to evaluate the prevention and treatment effects on liver injury, and the experimental result shows that: the geranium polysaccharide can obviously reduce the liver function index of an immune liver injury mouse.
The invention has the advantages that:
the polysaccharide component can be effectively and quickly obtained by the preparation method.
The liver protection activity of the geranium polysaccharide component is found, and the geranium polysaccharide component can be applied to the research and development of low-toxicity and high-efficiency liver protection medicines, and further develops and utilizes the geranium.
Drawings
FIG. 1 shows the intervention effect of Geranium wilfordii on liver function indexes (a: AST, b: ALT) of a ConA-induced mouse acute immune liver injury model;
in the figure, NC is a normal control group, MC is a model control group, PC is a bifendate positive control group, LL is a geranium polysaccharide low-dose group of 200mg/kg, and LH is a geranium polysaccharide high-dose group of 600 mg/kg. In comparison with the NC group, "#" indicates P <0.05, "# #" indicates P < 0.01, "# # ##" indicates P < 0.001; compared to the MC group, "+" indicates P <0.05, "+" indicates P < 0.01, and "+" indicates P < 0.001.
Detailed Description
The present invention is further illustrated by the following figures and examples, but is not limited thereto in any way, and any variations or modifications based on the teachings of the present invention are within the scope of the present invention.
Application of geranium polysaccharide in preparing liver-protecting medicine
The preparation method of the geranium polysaccharide comprises the following steps: pulverizing herba Erodii seu Geranii, defatting with methanol under reflux, extracting with water at 80 deg.C, precipitating with 80% ethanol, deproteinizing the crude polysaccharide obtained by precipitating with ethanol by sevege method, centrifuging, and discarding the precipitate to obtain refined herba Erodii seu Geranii polysaccharide.
The Geranium sibiricum polysaccharide has effect in protecting liver by reducing alanine Aminotransferase (ALT) value and aspartate Aminotransferase (AST) value in blood serum
The dose of Geranium sibiricum polysaccharide is 2-3 times per day, and 0.4-1.8g each time.
The dosage of Geranium polysaccharide is 1g for 3 times per day.
Adding pharmaceutically acceptable adjuvants into the Geranium polysaccharide, and making into tablet, hard capsule, soft capsule, powder, pill, and granule.
Geranium polysaccharide is used as active ingredient or medicinal carrier.
Example 1
Preparing the geranium crude polysaccharide: pulverizing herba Erodii seu Geranii, and defatting with methanol at 60 deg.C for 3 times. Decocting the defatted herba Erodii seu Geranii with hot water at 80 deg.C for 3 hr for 2 times, mixing extractive solutions, and concentrating under reduced pressure. Precipitating the concentrated extract with 80% ethanol, centrifuging, and removing supernatant to obtain crude polysaccharide of herba Erodii seu Geranii.
Example 2
And (3) refining geranium polysaccharide: re-dissolving the obtained geranium polysaccharide with distilled water, removing protein by a sevege method, centrifuging, discarding the precipitate for 5 times, and centrifuging until no precipitate exists. And finally, decompressing and concentrating the polysaccharide after protein removal, freezing and drying, and detecting the content of the polysaccharide by a sulfuric acid-phenol method to finally obtain the refined geranium polysaccharide.
Example 3
Liver-protecting efficacy research of geranium polysaccharide
1. Animal grouping, modeling and administration method
Geranium polysaccharide was prepared from example 2.
ICR mice were randomly divided into a normal control group, a model group, a positive group (bifendate 150 mg/kg), a geranium polysaccharide low dose group (200 mg/kg), and a geranium polysaccharide high dose group (600 mg/kg), each group containing 10 mice. The administration was performed by gavage, and the normal group and the model group were administered with physiological saline, and the other groups were administered with the corresponding dose of the drug 1 time for 1 day for 7 consecutive days. After 30min of the last administration, 12mg/kgConA is intravenously injected to the model group and each administration group to prepare an acute immune liver injury model, and normal groups are intravenously injected with normal saline with the same volume. After fasting for 7h without water deprivation, the animals were sacrificed by orbital bleeding and liver collection.
2. Serum liver function index detection
Blood is taken from eyeballs in a 1.5mL centrifuge tube, and the eyeballs are centrifuged at 4500r/min at normal temperature for 10min, and supernatant is left. Processing according to the procedures of alanine Aminotransferase (ALT) and aspartate Aminotransferase (AST) kits, and measuring the absorbance values (OD values) of ALT and AST in serum by using a microplate reader. And calculating the corresponding enzyme activity value according to the OD value by searching a standard curve.
The experimental results are shown in fig. 1, compared with the normal group, the AST and ALT values of the model group are obviously increased, and compared with the model group, the AST and ALT values of the positive drug and the administration groups with different doses are obviously reduced, and the dose dependence is shown. The results show that the geranium polysaccharide has a protective effect on immune liver injury mice.
In the mouse acute immunological liver injury test, the dosage of the geranium polysaccharide is 200-600 mg/kg/d. The dosage is 1.2-3.6g/d converted into human (calculated by adult weight 60 kg). In consideration of the difference in body weight of human and various other pathological conditions, the recommended dose is 2-3 times daily, 0.4-1.8g each time. The most common dosage is 1g each time 3 times daily.
In conclusion, the geranium polysaccharide has the characteristics of obvious liver protection activity and small toxic and side effects, and has wide application in the development of preparing liver protection medicines, particularly in the treatment of immunological liver injury diseases. Has important significance for further development and utilization of the geranium.
Claims (7)
1. Application of Geranium sibiricum polysaccharide in preparing liver-protecting medicine is provided.
2. The application of claim 1, wherein the geranium polysaccharide is prepared by the following steps: pulverizing herba Erodii seu Geranii, defatting with methanol under reflux, extracting with water at 80 deg.C, precipitating with 80% ethanol, deproteinizing the crude polysaccharide obtained by precipitating with ethanol by sevege method, centrifuging, and discarding the precipitate to obtain refined herba Erodii seu Geranii polysaccharide.
3. The use of claim 1, wherein Geranium sibiricum polysaccharide has liver protecting effect by reducing serum alanine Aminotransferase (ALT) and aspartate Aminotransferase (AST) levels.
4. The use of claim 1, wherein the dose of Geranium sibiricum polysaccharide is 2-3 times daily, 0.4-1.8g each time.
5. The use according to claim 1, wherein the geranium polysaccharide is administered in an amount of 1g per time and 3 times a day.
6. The preparation of the geranium polysaccharide as claimed in any one of claims 1 to 5, wherein the geranium polysaccharide is added with pharmaceutically acceptable auxiliary materials to prepare tablets, hard capsules, soft capsules, powders, pills and granules.
7. A pharmaceutical composition characterized by comprising the geranium polysaccharide of any one of claims 1 to 5 as an active ingredient or a pharmaceutically acceptable carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010078011.7A CN111297885B (en) | 2020-02-02 | 2020-02-02 | Application of geranium polysaccharide in preparing liver-protecting medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010078011.7A CN111297885B (en) | 2020-02-02 | 2020-02-02 | Application of geranium polysaccharide in preparing liver-protecting medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111297885A true CN111297885A (en) | 2020-06-19 |
| CN111297885B CN111297885B (en) | 2022-04-01 |
Family
ID=71150835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010078011.7A Active CN111297885B (en) | 2020-02-02 | 2020-02-02 | Application of geranium polysaccharide in preparing liver-protecting medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111297885B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114591449A (en) * | 2022-04-13 | 2022-06-07 | 云南中医药大学 | Geranium neutral polysaccharide and preparation method and application thereof |
| CN114605567A (en) * | 2022-04-13 | 2022-06-10 | 云南中医药大学 | Geranium wilfordii acidic polysaccharide and preparation method and application thereof |
| CN115252664A (en) * | 2022-02-18 | 2022-11-01 | 中以海德人工智能药物研发股份有限公司 | Application of effective component of Geranium wilfordii for treating or preventing viral hepatitis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106883303A (en) * | 2017-03-02 | 2017-06-23 | 河南中医药大学 | A kind of preparation method and application of geranium wilfordii polysaccharide and oligosaccharide |
-
2020
- 2020-02-02 CN CN202010078011.7A patent/CN111297885B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106883303A (en) * | 2017-03-02 | 2017-06-23 | 河南中医药大学 | A kind of preparation method and application of geranium wilfordii polysaccharide and oligosaccharide |
Non-Patent Citations (2)
| Title |
|---|
| MIN HUANG: "Identification of anti-inflammatory fractions of Geranium wilfordii using tumor necrosis factor-alpha as a drug target on Herbochip® - an array-based high throughput screening platform", 《BMC COMPLEMENTARY & ALTERNATIVE MEDICINE》 * |
| 郑铁等: "老鹳草水提取物对四氯化碳所致小鼠急性肝损伤的保护作用", 《延边大学医学学报》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115252664A (en) * | 2022-02-18 | 2022-11-01 | 中以海德人工智能药物研发股份有限公司 | Application of effective component of Geranium wilfordii for treating or preventing viral hepatitis |
| CN114591449A (en) * | 2022-04-13 | 2022-06-07 | 云南中医药大学 | Geranium neutral polysaccharide and preparation method and application thereof |
| CN114605567A (en) * | 2022-04-13 | 2022-06-10 | 云南中医药大学 | Geranium wilfordii acidic polysaccharide and preparation method and application thereof |
| CN114605567B (en) * | 2022-04-13 | 2023-01-10 | 云南中医药大学 | Geranium wilfordii acidic polysaccharide and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111297885B (en) | 2022-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111297885B (en) | Application of geranium polysaccharide in preparing liver-protecting medicine | |
| CN104547826B (en) | Galangal rhizome extract treats the medical usage of dysmenorrhoea | |
| CN102271698A (en) | Pharmaceutical composition and use for preparing medicament thereof | |
| CN113151389A (en) | Ginseng glycopeptide, preparation method and medical application thereof | |
| CN112961262A (en) | Passiflora edulis pericarp acidic polysaccharide, preparation method and application thereof | |
| CN103446525B (en) | Treat dermopathic Chinese medicine composition and its preparation method and application | |
| CN107951980B (en) | Application of hosta plantaginea flower and extract thereof in preparing medicine for treating chronic prostatitis | |
| CN111166820B (en) | Traditional Chinese medicine composition containing fingered citron, preparation and application | |
| CN115089694B (en) | Glycyrrhiza protein extract and new application thereof | |
| CN106822338B (en) | Compound composition for reducing blood sugar and blood fat and preventing and/or treating diabetes and complications thereof and application thereof | |
| WO1993013787A1 (en) | Immunopotentiating agent | |
| CN111297887B (en) | Preparation method and application of liver-protecting active component of Yunnan ginseng | |
| CN1219539C (en) | Immune regulator prepared from waste material in preparing Mailuoning injection process and its use in producing medicine | |
| CN103655597B (en) | A kind of purposes of the many carbohydrates and their derivative of Rhizoma Curculiginis | |
| CN100337671C (en) | Chinese traditional medicine for treating thrombocytopenia | |
| CN1060051C (en) | Anti-cancer compn. and prepn. thereof | |
| CN101991678B (en) | Application of India madder root in preparing medicine for preventing and treating kidney disease | |
| CN102091161B (en) | Total lignan extract of stalkedfruit pricklyash bark for treating arthritis | |
| CN102008534A (en) | Antitubercular pharmaceutical composition containing balloonflower root extract | |
| CN106822152A (en) | A kind of pharmaceutical composition and its application | |
| CN101642495A (en) | Method for producing traditional Chinese medicine preparation with functions of protecting liver, lowering enzymes and enhancing immunity | |
| CN106902330B (en) | Traditional Chinese medicine preparation for treating rheumatic arthritis and rheumatalgia and preparation method and application thereof | |
| CN100333751C (en) | Chinese traditional medicine for curing cholestatic hepatitis and preparing method | |
| CN101073621B (en) | Medicinal composition for treating rheumatic pain | |
| CN111297886A (en) | Application of gentian polysaccharide in preparation of medicine for preventing or treating liver injury diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |